Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

Abstract

Introduction: Cyclin-dependent kinases (CDKs) regulate cell cycle progression. Certain CDKs (e.g., CDK7, CDK9) also control cellular transcription. Consequently, CDKs represent attractive targets for anticancer drug development, as their aberrant expression is common in diverse malignancies, and CDK inhibition can trigger apoptosis. CDK inhibition may be particularly successful in hematologic malignancies, which are more sensitive to inhibition of cell cycling and apoptosis induction.

Areas covered: A number of CDK inhibitors, ranging from pan-CDK inhibitors such as flavopiridol (alvocidib) to highly selective inhibitors of specific CDKs (e.g., CDK4/6), such as PD0332991, that are currently in various phases of development, are profiled in this review. Flavopiridol induces cell cycle arrest, and globally represses transcription via CDK9 inhibition. The latter may represent its major mechanism of action via down-regulation of multiple short-lived proteins. In early phase trials, flavopiridol has shown encouraging efficacy across a wide spectrum of hematologic malignancies. Early results with dinaciclib and PD0332991 also appear promising.

Expert opinion: In general, the antitumor efficacy of CDK inhibitor monotherapy is modest, and rational combinations are being explored, including those involving other targeted agents. While selective CDK4/6 inhibition might be effective against certain malignancies, broad-spectrum CDK inhibition will likely be required for most cancers.

Keywords::

• alvocidib
• cyclin-dependent kinase inhibitors
• dinaciclib
• flavopiridol
• Mcl-1
• PD0332991
• roscovitine
• SCH727965
• seliciclib
• targeted therapies

Acknowledgements

The authors acknowledge Y Dai, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA for kindly providing Figure 1, which was subsequently modified by the authors.

Notes

This box summarizes key points contained in the article.